Original Research published: 14 August 2017 doi: 10.3389/fendo.2017.00199
Albuminuria Reduction after High Dose of Vitamin D in Patients with Type 1 Diabetes Mellitus: A Pilot Study João Soares Felício*, Alana Ferreira de Oliveira, Amanda Soares Peixoto, Ana Carolina Contente Braga de Souza, João Felício Abrahão Neto, Franciane Trindade Cunha de Melo, Carolina Tavares Carvalho, Manuela Nascimento de Lemos, Sávio Diego Nascimento Cavalcante, Fabricio de Souza Resende, Márcia Costa dos Santos, Ana Regina Motta, Luísa Corrêa Janaú, Elizabeth Sumi Yamada and Karem Miléo Felício University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Belém, Brazil
Edited by: Åke Sjöholm, Gävle Hospital, Sweden Reviewed by: Maria K. Svensson, Uppsala University, Sweden Hidetaka Hamasaki, Hamasaki Clinic, Japan *Correspondence: João Soares Felício [email protected] Specialty section: This article was submitted to Diabetes, a section of the journal Frontiers in Endocrinology Received: 23 June 2017 Accepted: 31 July 2017 Published: 14 August 2017 Citation: Felício JS, Oliveira AFd, Peixoto AS, Souza ACCBd, Abrahão Neto JF, de Melo FTC, Carvalho CT, Lemos MNd, Cavalcante SDN, Resende FdS, Santos MCd, Motta AR, Janaú LC, Yamada ES and Felício KM (2017) Albuminuria Reduction after High Dose of Vitamin D in Patients with Type 1 Diabetes Mellitus: A Pilot Study. Front. Endocrinol. 8:199. doi: 10.3389/fendo.2017.00199
Background: Some studies suggest an association between diabetic kidney disease (DKD) and vitamin D (VD), but there is no data about the effect of high dose of VD on DKD in type 1 diabetes mellitus (T1DM). Our pilot study aims to evaluate albuminuria reduction in patients with T1DM supplemented with high dose of VD. Methods: 22 patients received doses of 4,000 and 10,000 IU/day of cholecalciferol for 12 weeks according to patient’s previous VD levels. They were submitted to continuous glucose monitoring system, 24 hours ambulatory blood pressure monitoring and urine albumin-to-creatinine ratio before and after VD supplementation. Results: There was a reduction of DKD prevalence at the end of the study (68 vs 32%; p = 0.05), with no changes on insulin doses, glycated hemoglobin, glycemic variability and blood pressure values. A correlation between percentage variation of VD levels (ΔVD) and albuminuria at the end of the study was presented (r = −0.5; p
Albuminuria Reduction after High Dose of Vitamin D in Patients with Type 1 Diabetes Mellitus: A Pilot Study João Soares Felício*, Alana Ferreira de Oliveira, Amanda Soares Peixoto, Ana Carolina Contente Braga de Souza, João Felício Abrahão Neto, Franciane Trindade Cunha de Melo, Carolina Tavares Carvalho, Manuela Nascimento de Lemos, Sávio Diego Nascimento Cavalcante, Fabricio de Souza Resende, Márcia Costa dos Santos, Ana Regina Motta, Luísa Corrêa Janaú, Elizabeth Sumi Yamada and Karem Miléo Felício University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Belém, Brazil
Edited by: Åke Sjöholm, Gävle Hospital, Sweden Reviewed by: Maria K. Svensson, Uppsala University, Sweden Hidetaka Hamasaki, Hamasaki Clinic, Japan *Correspondence: João Soares Felício [email protected] Specialty section: This article was submitted to Diabetes, a section of the journal Frontiers in Endocrinology Received: 23 June 2017 Accepted: 31 July 2017 Published: 14 August 2017 Citation: Felício JS, Oliveira AFd, Peixoto AS, Souza ACCBd, Abrahão Neto JF, de Melo FTC, Carvalho CT, Lemos MNd, Cavalcante SDN, Resende FdS, Santos MCd, Motta AR, Janaú LC, Yamada ES and Felício KM (2017) Albuminuria Reduction after High Dose of Vitamin D in Patients with Type 1 Diabetes Mellitus: A Pilot Study. Front. Endocrinol. 8:199. doi: 10.3389/fendo.2017.00199
Background: Some studies suggest an association between diabetic kidney disease (DKD) and vitamin D (VD), but there is no data about the effect of high dose of VD on DKD in type 1 diabetes mellitus (T1DM). Our pilot study aims to evaluate albuminuria reduction in patients with T1DM supplemented with high dose of VD. Methods: 22 patients received doses of 4,000 and 10,000 IU/day of cholecalciferol for 12 weeks according to patient’s previous VD levels. They were submitted to continuous glucose monitoring system, 24 hours ambulatory blood pressure monitoring and urine albumin-to-creatinine ratio before and after VD supplementation. Results: There was a reduction of DKD prevalence at the end of the study (68 vs 32%; p = 0.05), with no changes on insulin doses, glycated hemoglobin, glycemic variability and blood pressure values. A correlation between percentage variation of VD levels (ΔVD) and albuminuria at the end of the study was presented (r = −0.5; p
